Solventum Corporation (SOLV) is a publicly traded Healthcare sector company. As of May 21, 2026, SOLV trades at $76.13 with a market cap of $13.18B and a P/E ratio of 9.25. SOLV moved +1.79% today. Year to date, SOLV is -5.78%; over the trailing twelve months it is +1.91%. Its 52-week range spans $60.70 to $88.20. Analyst consensus is buy with an average price target of $82.70. Rallies surfaces SOLV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Solventum jumps after Q1 beat, nudges 2026 adjusted EPS toward high end: Solventum shares are higher after reporting Q1 2026 results ahead of expectations and lifting its adjusted EPS outlook toward the high end of its $6.40–$6.60 full-year range. The company also reaffirmed 2026 organic sales growth of 2%–3% and free cash flow guidance of about $200 million.
| Metric | Value |
|---|---|
| Price | $76.13 |
| Market Cap | $13.18B |
| P/E Ratio | 9.25 |
| EPS | $8.21 |
| Dividend Yield | 0.00% |
| 52-Week High | $88.20 |
| 52-Week Low | $60.70 |
| Volume | 992.44K |
| Avg Volume | 0 |
| Revenue (TTM) | $8.26B |
| Net Income | $1.43B |
| Gross Margin | 53.67% |
12 analysts cover SOLV: 0 strong buy, 7 buy, 3 hold, 2 sell, 0 strong sell. Consensus rating is buy. Average price target: $82.70.